Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | April 23, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 169,935 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 56,000 · Balance 225,935 Row 2 · 2019-04-23 · Sale · Disposed 56,000 · Balance 169,935 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 113,227 |
Reported balance
After 2019-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-23 · Exercise / conversion · Disposed 56,000 · Balance 113,227 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,698 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,698 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 53 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 53 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019.
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2019 Filed Apr 24, 2019 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 56,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005147 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,227 Underlying: Common shares · 56,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 56,000 | $76.00 | $4,256,000.00 |
DisclosureSEC source: 0001179110-19-005147 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,935 Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 56,000 | $47.00 | $2,632,000.00 |
DisclosureSEC source: 0001179110-19-005147 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,246 | $78.00 | $175,188.00 |
DisclosureSEC source: 0001179110-19-003117 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,935 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 15,221 | $77.23 | $1,175,517.83 |
DisclosureSEC source: 0001179110-19-003117 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,181 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 138,121 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002642 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,121 Underlying: Common shares · 138,121 shares Expires 2029-02-21 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 46,040 on February 22, 2020, 46,040 on February 22, 2021, and 46,041 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 26,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002642 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,402 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 11,106 | $60.13 | $667,803.78 |
DisclosureSEC source: 0001179110-18-003321 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,052 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 12,726 | $60.55 | $770,559.30 |
DisclosureSEC source: 0001179110-18-003321 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,158 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 104,642 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · derivative · entry 32 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,642 Underlying: Common shares · 104,642 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $59.67 | $5,966.90 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 30 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,125 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 77 | $59.67 | $4,594.44 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 29 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,225 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,985 | $59.67 | $178,100.03 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 28 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,302 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,206 | $59.66 | $489,569.96 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 27 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,287 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10 | $59.66 | $596.58 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 26 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,493 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,200 | $59.66 | $190,896.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 25 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,503 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,794 | $59.65 | $285,962.10 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 24 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,703 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $59.65 | $35,787.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 23 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,497 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,700 | $59.64 | $101,388.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 22 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,097 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $59.64 | $29,817.50 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 21 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,797 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $59.63 | $95,408.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 20 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,297 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 22,500 | $59.60 | $1,341,000.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 19 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,897 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $59.60 | $5,959.50 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 18 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,397 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $59.59 | $29,795.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 17 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,497 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $59.59 | $29,792.50 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 16 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,997 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $59.58 | $29,790.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 15 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,497 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 180 | $59.56 | $10,720.80 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 14 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,997 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 574 | $59.55 | $34,178.83 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,177 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 226 | $59.54 | $13,456.04 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 12 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,751 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 989 | $59.53 | $58,875.17 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 11 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,977 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 728 | $59.52 | $43,330.56 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,966 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $59.52 | $11,903.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,694 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,172 | $59.51 | $69,745.72 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 8 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,894 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $59.50 | $71,400.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,066 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 441 | $59.50 | $26,237.30 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,266 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,419 | $59.49 | $84,416.31 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,707 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $59.48 | $17,844.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,126 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $59.47 | $65,417.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,426 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 104,642 | $38.40 | $4,018,252.80 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $59.82 | $71,778.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 30 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,416 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $59.81 | $5,981.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 29 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,616 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $59.81 | $5,980.75 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 28 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,716 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $59.80 | $89,700.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 27 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,816 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $59.80 | $11,959.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 26 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,316 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $59.79 | $35,874.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 25 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,516 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 304 | $59.79 | $18,174.64 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 24 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,116 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $59.78 | $53,802.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 23 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,420 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $59.78 | $77,707.50 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 22 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,320 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $59.77 | $149,425.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 21 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,620 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 740 | $59.77 | $44,226.10 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 20 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,120 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.